Last reviewed · How we verify

NCT03966534

Blood Test Order and Culture Contamination

Completed NA Last updated 29 May 2019
What this trial tests

NA trial testing Blood diversion in Blood Culture Contamination in 970 participants. Completed in 28 February 2019.

Timeline
1 September 2018
Primary endpoint
28 February 2019
28 February 2019

Quick facts

Lead sponsorShaare Zedek Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment970
Start date1 September 2018
Primary completion28 February 2019
Estimated completion28 February 2019
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Shaare Zedek Medical Center

Who can join

18 and older, any sex, with Blood Culture Contamination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized partially controlled study to examine the effect of blood diversion into a heparin lithium tube on the incidence of blood culture contamination.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Modification of Blood Test Draw Order to Reduce Blood Culture Contamination: A Randomized Clinical Trial.
    Zimmerman FS, Karameh H, Ben-Chetrit E, Zalut T, et al · · 2020 · cited 16× · PMID 31570942 · DOI 10.1093/cid/ciz971

Verify or expand the search:

Other recruiting trials for Blood Culture Contamination

Currently open trials in the same condition.

Other Shaare Zedek Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing